Exclusive Summary

• Pamidronate Disodium is off-patent globally with an established generic market, facing clear demand especially in low-to-middle-income countries, and holds potential for FDA/EMA certification.
• The product has passed China's consistency evaluation, ensuring high quality standards and offering a significant cost advantage over the originator drug, meeting the growing global demand for bone-related disease treatments.
• Pamidronate Disodium is listed on the WHO Essential Medicines List and is guideline-recommended as a first-/second-line treatment for various bone disorders, securing its strong clinical position.
• Being the first generic in China to pass consistency evaluation offers a high degree of quality assurance, facilitating rapid entry into international markets for distribution partnerships.
• The product holds substantial market potential, capable of reaching patient populations across multiple countries and regions, particularly attractive to areas in need of cost-effective and efficient treatment options.

Asset Materials

Contact Us for Full Materials